Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
More than 200 people participated in the Pulmonary Hypertension Association Southern California O2breathe walk. The April 15 event in Long Beach, California, raised more than $17,000, almost double the 2022 total.
The latest edition of Advances in Pulmonary Hypertension addresses basic and clinical pulmonary hypertension (PH) research. Advances is the Pulmonary Hypertension Association’s quarterly peer-reviewed clinical journal. This issue also covers new PH guidelines and includes all abstracts from PHA 2022 International PH Conference and Scientific Sessions.
Is your child or teen with pulmonary hypertension dreaming of meeting new friends while participating in fun outdoor activities? Now is the time to look into camps that accommodate children with special needs – and sign yours up. Check out our tips to find a camp with trained health care professionals that meets your child’s interests.
Discover new ideas for pulmonary arterial hypertension (PAH) risk assessment at the Pulmonary Hypertension Association’s PH Professional Network Symposium. The Sept. 28-30 event in Arlington, Virginia, will feature a session on “Balancing the Art and Science of PAH Risk Stratification,” presented by Susanne McDevitt, D.N.P., ANCP-BC and Melisa Wilson, D.N.P., ACNP, APRN-BC. Learn more about the session and how to submit a late-breaking abstract.
The first issue of Pathlight this year examines the state of PH. In the cover story, artist Suzanne Miller describes how she manages her PH through mind and body wellness. The issue also includes an in-depth look at new guidelines for PH treatment and diagnosis.
Kevin Heyen, vice president of development and industry relations for the Pulmonary Hypertension Association, recently stepped behind the bar in his hometown to support PHA. Kevin’s celebrity bartender stint was an example of creative ways the PHA community raises money to support pulmonary hypertension research and awareness.
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more
